Efficacy and safety of tirofiban as an adjunctive therapy in patients with acute ST-segment elevation myocardial infarction undergoing percutaneous transluminal coronary angioplasty

Sanjay Sharma; Seema Gupta; Sanjeev Bhat; Zahid Gillani; Dinesh Kumar; Rajesh Kumar

doi:10.5455/njppp.2016.6.0512413062016

2024, Vol: 14, Issue: 4

14 / 4Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

Required files to be uploaded

Authorship Declaration

« Previous Article

Original Research

Online Publishing Date:
23 / 06 / 2016

Natl J Physiol Pharm Pharmacol. 2016; 6(6): 531-536

doi: 10.5455/njppp.2016.6.0512413062016

Efficacy and safety of tirofiban as an adjunctive therapy in patients with acute ST-segment elevation myocardial infarction undergoing percutaneous transluminal coronary angioplasty

Sanjay Sharma, Seema Gupta, Sanjeev Bhat, Zahid Gillani, Dinesh Kumar, Rajesh Kumar.

Abstract
Background: The introduction of stents and the use of platelet glycoprotein IIb/IIIa inhibitors, either alone or in combination with reduced-dose fibrinolytic therapy, has allowed percutaneous coronary intervention (PCI) to be performed more safely and synergistically following pharmacologic reperfusion therapy.

Aims and Objectives: The present study was conducted to evaluate the efficacy and safety of tirofiban as an adjunct to angioplasty/stenting in acute ST-elevation myocardial infarction (MI) patients.

Materials and Methods: A total of 156 consecutive patients diagnosed with acute ST-segment elevation MI (STEMI) presenting within 12 h of symptoms were randomly allocated to primary PCI alone or primary PCI along with tirofiban. Clinical characteristics, angiographic findings (including thrombolysis in MI [TIMI] flow rate), and ST-segment resolution were compared post-procedurally; left ventricular ejection fraction (LVEF) and major adverse cardiac events (MACE, including death, reinfarction, and target vessel revascularization) were compared at 30 days clinical follow-up.

Results: Post-procedurally, TIMI Grade 3 reflow was significantly different between two groups (P = 0.01) and was associated with better in-hospital outcomes in tirofiban group compared with control group. Greater resolution of ST-elevation was achieved in patients given tirofiban than in non-tirofiban group, and the results were highly significant. Statistically significant improvement in LVEF was also observed in tirofiban group. There was non-significant difference in MACE and bleeding complications between two groups.

Conclusion: Adjunctive tirofiban therapy for patients with acute STEMI, who underwent primary PCI, seems to be safe and effective treatment modality to achieve improved reperfusion, better LVEF, and clinical outcome at 30 days follow-up.

Key words: Tirofiban; Percutaneous Coronary Intervention; ST-segment Elevation Myocardial Infarction

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Sanjay Sharma Articles by Seema Gupta Articles by Sanjeev Bhat Articles by Zahid Gillani Articles by Dinesh Kumar Articles by Rajesh Kumar
	on Google
	on Google Scholar

How to Cite this Article

Pubmed Style

Sanjay Sharma, Seema Gupta, Sanjeev Bhat, Zahid Gillani, Dinesh Kumar, Rajesh Kumar. Efficacy and safety of tirofiban as an adjunctive therapy in patients with acute ST-segment elevation myocardial infarction undergoing percutaneous transluminal coronary angioplasty. Natl J Physiol Pharm Pharmacol. 2016; 6(6): 531-536. doi:10.5455/njppp.2016.6.0512413062016

Web Style

Sanjay Sharma, Seema Gupta, Sanjeev Bhat, Zahid Gillani, Dinesh Kumar, Rajesh Kumar. Efficacy and safety of tirofiban as an adjunctive therapy in patients with acute ST-segment elevation myocardial infarction undergoing percutaneous transluminal coronary angioplasty. https://www.njppp.com/?mno=226747 [Access: March 14, 2024]. doi:10.5455/njppp.2016.6.0512413062016

AMA (American Medical Association) Style

Sanjay Sharma, Seema Gupta, Sanjeev Bhat, Zahid Gillani, Dinesh Kumar, Rajesh Kumar. Efficacy and safety of tirofiban as an adjunctive therapy in patients with acute ST-segment elevation myocardial infarction undergoing percutaneous transluminal coronary angioplasty. Natl J Physiol Pharm Pharmacol. 2016; 6(6): 531-536. doi:10.5455/njppp.2016.6.0512413062016

Vancouver/ICMJE Style

Sanjay Sharma, Seema Gupta, Sanjeev Bhat, Zahid Gillani, Dinesh Kumar, Rajesh Kumar. Efficacy and safety of tirofiban as an adjunctive therapy in patients with acute ST-segment elevation myocardial infarction undergoing percutaneous transluminal coronary angioplasty. Natl J Physiol Pharm Pharmacol. (2016), [cited March 14, 2024]; 6(6): 531-536. doi:10.5455/njppp.2016.6.0512413062016

Harvard Style

Sanjay Sharma, Seema Gupta, Sanjeev Bhat, Zahid Gillani, Dinesh Kumar, Rajesh Kumar (2016) Efficacy and safety of tirofiban as an adjunctive therapy in patients with acute ST-segment elevation myocardial infarction undergoing percutaneous transluminal coronary angioplasty. Natl J Physiol Pharm Pharmacol, 6 (6), 531-536. doi:10.5455/njppp.2016.6.0512413062016

Turabian Style

Sanjay Sharma, Seema Gupta, Sanjeev Bhat, Zahid Gillani, Dinesh Kumar, Rajesh Kumar. 2016. Efficacy and safety of tirofiban as an adjunctive therapy in patients with acute ST-segment elevation myocardial infarction undergoing percutaneous transluminal coronary angioplasty. National Journal of Physiology, Pharmacy and Pharmacology, 6 (6), 531-536. doi:10.5455/njppp.2016.6.0512413062016

Chicago Style

Sanjay Sharma, Seema Gupta, Sanjeev Bhat, Zahid Gillani, Dinesh Kumar, Rajesh Kumar. "Efficacy and safety of tirofiban as an adjunctive therapy in patients with acute ST-segment elevation myocardial infarction undergoing percutaneous transluminal coronary angioplasty." National Journal of Physiology, Pharmacy and Pharmacology 6 (2016), 531-536. doi:10.5455/njppp.2016.6.0512413062016

MLA (The Modern Language Association) Style

Sanjay Sharma, Seema Gupta, Sanjeev Bhat, Zahid Gillani, Dinesh Kumar, Rajesh Kumar. "Efficacy and safety of tirofiban as an adjunctive therapy in patients with acute ST-segment elevation myocardial infarction undergoing percutaneous transluminal coronary angioplasty." National Journal of Physiology, Pharmacy and Pharmacology 6.6 (2016), 531-536. Print. doi:10.5455/njppp.2016.6.0512413062016

APA (American Psychological Association) Style

Sanjay Sharma, Seema Gupta, Sanjeev Bhat, Zahid Gillani, Dinesh Kumar, Rajesh Kumar (2016) Efficacy and safety of tirofiban as an adjunctive therapy in patients with acute ST-segment elevation myocardial infarction undergoing percutaneous transluminal coronary angioplasty. National Journal of Physiology, Pharmacy and Pharmacology, 6 (6), 531-536. doi:10.5455/njppp.2016.6.0512413062016

Author Login Reviewer Login About Publisher Editorial Policies Editorial Review Policy Peer Review Policy Editorial & Peer Review Process Publication Ethics and Publication Malpractice Statement Conflict of Interest Policy Plagiarism Policy Protection of Research Participants (Statement On Human And Animal Rights)Corrections, Retractions & Expressions of Concern Self-Archiving Policies Statement of Informed Consent Advertising Policy Terms of Use License Information Copyright Information

About National Journal of Physiology, Pharmacy and Pharmacology

Contact Information

How to cite this article


About National Journal of Physiology, Pharmacy and Pharmacology National Journal of Physiology, Pharmacy and Pharmacology is a monthly peer reviewed journal. The journal is having open access polic ... Read more. For best results, please use Internet Explorer or Google Chrome.	Contact Information Publisher publishernjppp@gmail.com Editorial query editornjppp1@gmail.com MOB - 8780040272